Aarti Pharmalabs delivered exceptional financial performance in the quarter ended June 2026, with consolidated net profit surging 65.4% year-on-year to ₹76.14 crore compared to ₹49.50 crore in the corresponding quarter of the previous year. The company also demonstrated strong sequential growth with profit increasing 24.6% quarter-on-quarter. According to reports from Business Standard and The Economic Times, this significant profit growth demonstrates the company's robust operational performance during the quarter.
The company's sales revenue increased 38.7% year-on-year to ₹535.79 crore in Q1 FY2026, though it declined 8.0% quarter-on-quarter. As reported by Business Standard and The Economic Times, this substantial revenue growth indicates robust demand for the company's pharmaceutical products and services, with the sequential decline likely attributed to seasonal factors or market dynamics.
The company's operating profit margin (OPM) improved to 25.40% in the June 2026 quarter, compared to 24.20% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin expansion reflects better cost management and operational efficiency during the quarter. Profit Before Tax (PBT) increased 66.2% year-on-year to ₹101.06 crore, up 23.7% quarter-on-quarter, indicating strong operational performance across all profitability metrics.
On the cost front, total expenses increased 36.5% year-on-year to ₹442.59 crore, while declining 14.0% quarter-on-quarter. Cost of materials consumed rose 31.6% year-on-year to ₹251.87 crore, and employee benefits expense increased 22.0% year-on-year to ₹50.32 crore. Finance costs surged 89.5% year-on-year to ₹12.88 crore, while depreciation and amortisation expenses rose 31.8% year-on-year to ₹30.03 crore. The company has approved a ₹149 crore capex plan for capacity addition of an intermediate block to serve intermediate and CDMO customers, with the expansion involving 405 KL of new capacity to be added within one year.
The strong quarterly performance drove Aarti Pharmalabs shares to hit the upper circuit of 20% at ₹823 following the earnings announcement, as reported by The Economic Times. The stock opened with a sharp gap-up at ₹763.00 before touching the maximum permissible limit of ₹823.00 on the stock exchanges. Following the earnings release, the stock opened with a sharp gap-up at ₹763.00 before touching the maximum permissible limit of ₹823.00 on the stock exchanges. The company has also announced board restructuring and leadership transition, with the board reconstituting key governance bodies including the Audit Committee, CSR Committee, and Stakeholders Relationship Committee. The stock has since extended its rally, gaining 33.4% over two days to trade at ₹896.05 during Tuesday's session, as reported by The Economic Times, with the expansion project targeted for completion within one year and funded through a combination of internal accruals and borrowings.
